.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Mallinckrodt
Cantor Fitzgerald
US Army
Baxter
Merck
Dow
AstraZeneca
Express Scripts
Harvard Business School

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021269

« Back to Dashboard
NDA 021269 describes CARDURA XL, which is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. Additional details are available on the CARDURA XL profile page.

The generic ingredient in CARDURA XL is doxazosin mesylate. There are thirteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

Summary for NDA: 021269

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Genitourinary Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 021269

Mechanism of ActionAdrenergic alpha-Antagonists

Suppliers and Packaging for NDA: 021269

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CARDURA XL
doxazosin mesylate
TABLET, EXTENDED RELEASE;ORAL 021269 NDA Roerig 0049-2710 0049-2710-30 30 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE (0049-2710-30)
CARDURA XL
doxazosin mesylate
TABLET, EXTENDED RELEASE;ORAL 021269 NDA Roerig 0049-2720 0049-2720-30 30 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE (0049-2720-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 4MG BASE
Approval Date:Feb 22, 2005TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 8MG BASE
Approval Date:Feb 22, 2005TE:RLD:Yes

Expired Orange Book Patents for NDA: 021269

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
CARDURA XL
doxazosin mesylate
TABLET, EXTENDED RELEASE;ORAL021269-002Feb 22, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
Mallinckrodt
Federal Trade Commission
Fuji
Farmers Insurance
Chubb
AstraZeneca
Julphar
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot